Janumet XR CP (Sitagliptin/Metformin)

Introduction

Janumet XR CP contains Sitagliptin with Metformin. It is designed to treat Type 2 Diabetes Mellitus (T2DM). The combination uses the complementary mechanisms between two well-established antidiabetic drugs to achieve better glycemic management.

• Sitagliptin inhibits Dipeptidyl Peptidase-4 (DPP-4).
• Metformin reduces the production of hepatic sugar and increases insulin sensitivity.

Janumet XR CP has been formulated in an extended release (XR), allowing for a once-daily dose with better GI tolerance.

Pharmacology

Sitagliptin

• It inhibits DPP-4, which is responsible for the degradation of incretin hormones GLP-1 & GIP.
• It increases the insulin secretion and decreases the glucagon release by prolonging its incretin-like action.
• It leads to an improvement in postprandial glucose and fasting blood sugar levels, without hypoglycemia.

Metformin

• Reduces basal sugar production by reducing hepatic glucose synthesis.
• Increases the peripheral glucose absorption and utilization in particular muscle tissue.
• It improves insulin sensitivity, and it has a positive effect on lipid metabolism.
• Low risk of hypoglycemia because it does not stimulate the insulin secretion.

Indications

The Janumet XR CP product is recommended for:

• Diet and exercise are adjuncts to the treatment of Type 2 Diabetes Mellitus.
• Metformin is used as the initial treatment for patients who are not adequately controlled with metformin.
• Use in conjunction with insulin or other anti-diabetic drugs.
• This product is not indicated for Type 1 Diabetes or Diabetic Ketoacidosis.

Dosage and Administration

General Guidelines:

• Janumet XR CP is taken once daily with the evening meal to maximize absorption and minimize gastrointestinal side effects.
• The tablets should not be crushed or chewed.

Typical Dosing:

• It depends on your patient’s glycemic level, current treatment, and tolerance.
• Common starting dose: Janumet XR CP 50 mg/500 mg or 50 mg/1000 mg sitagliptin/metformin once daily.
• The dose can be adjusted based on the glycemic responses, with a limit of 2000 mg/day metformin or 100 mg/day sitagliptin.
• Before initiation, and then periodically afterward, the renal function should be evaluated.

Pharmacokinetics

• Sitagliptin rapidly absorbs, reaching a peak plasma concentration in 1-4 hours.
• Metformin XR absorbs slowly, resulting in sustained plasma concentration.
• Sitagliptin is mainly excreted unchanged in the kidneys.
• Metformin is excreted unchanged through the kidneys. Renal function influences drug clearance.

Contraindications

• Renal impairment (eGFR <30 mL/min/1.73m²).
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Hypersensitivity to sitagliptin, metformin, or any excipients.
• Hypoxia can be caused by certain conditions (e.g., heart failure or respiratory failure).
• Hepatic impairment (metformin contraindicated in severe cases).
• Drinking alcohol is linked to an increased chance of developing lactic acidosis.

Side Effects

Common Side Effects:

• Gastrointestinal: Nausea, diarrhea, abdominal discomfort (mainly from metformin).
• Upper respiratory tract infections (associated with sitagliptin).
• Headache.

Serious Side Effects:

• Lactic acidosis: Rare, but not life-threatening. Signs include myalgia and malaise. breathing problems, and malaise.
• Hypoglycemia: It is not common when used by itself, but the risks increase when combined with other hypoglycemic drugs.
• Pancreatitis (reported with sitagliptin): Severe abdominal pain requires immediate evaluation.
• Allergic reactions (rash, swelling).

Precautions

• Keep track of renal function on a regular basis and adjust dosage or stop when renal function decreases.
• Careful with elderly patients with impaired kidney function.
• Take a break from metformin for a few days before the iodine contrast imaging to lower the risk of lactic acidosis.
• Check for any signs of pancreatitis.
• Reduce doses or stop taking it in the event of severe stomach signs.
• Inform patients about the signs of lactic acidosis and hypoglycemia.

Drug Interactions

• The effects of drugs on the function of the kidneys (NSAIDs, diuretics, and ACE inhibitors) may raise the levels of metformin.
• Certain anti-diabetic medications can raise the risk of developing hypoglycemia.
• Beware of concomitant use with GLP-1 receptors, inhibitors of DPP-4, or antagonists.
• Certain medications (e.g. and cationic substances that are eliminated through renal tubular secretion) can increase the amount of metformin in your body.

Use in Special Populations

• Pregnancy: Category B is to be used only if required.
• Lactation: Metformin can be excreted through the breastmilk of infants; be sure to monitor them.
• Pediatrics: Insufficient evidence of safety or efficacy less than 18 years old.
• Elderly: The risk of increased lactose is due to a decrease in kidney function.

Monitoring Parameters

• Glycemic control (HbA1c, fasting glucose).
• Renal function (serum creatinine, eGFR).
• Liver function tests.
• Vitamin B12 levels (long-term metformin use may cause deficiency).
• Signs of pancreatitis.

Patient Counseling Points

• Consume food for a reduction in stomach discomfort.
• Avoid chewing or crushing extended-release tablets.
• Maintain diet and exercise regimen.
• If you notice signs of hypoglycemia or lactic acidosis right away.
• Continuously monitor your blood glucose levels and check in with your medical professional.

Storage

• Place in a cool, dry place free of heat and moisture.
• Make sure that the area is safe for young children.

Summary

Janumet XR CP (Sitagliptin/Metformin) is an effective, once-daily oral combination medication for managing Type 2 Diabetes Mellitus. It combines two complementary mechanisms—enhanced insulin secretion and reduced hepatic glucose production—improving glycemic control with a relatively low risk of hypoglycemia.